Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 212-215

  Aznaouridis, Konstantinos ^a   Vlachopoulos, Charalambos ^a   Dima, Ioanna ^a   Vasiliadou, Carmen ^a   Ioakeimidis, Nikolaos ^a   Baou, Katerina ^a   Stefanadi, Elli ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Extracellular matrix; Fibrinolytic factors; Haemostasis; Matrix metalloproteinases; Thrombosis; Tissue inhibitors of metalloproteinases

Indexed keywords

FIBRINOGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HEMOSTASIS; LETTER; LINEAR REGRESSION ANALYSIS; POPULATION; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; UNIVARIATE ANALYSIS;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; EXTRACELLULAR MATRIX; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK FACTORS; THROMBOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 35248836004     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.12.015     Document Type: Letter

References (21)

1. Garcia-Touchard A., Henry T.D., Sangiorgi G., et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 25 (2005) 1119-1127
2. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 Part 19 (2002) 3719-3727
3. Sundstrom J., Evans J.C., Benjamin E.J., et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart study. Eur Heart J 25 (2004) 1509-1516
4. Tayebjee M.H., Lim H.S., Nadar S., MacFadyen R.J., and Lip G.Y. Tissue inhibitor of metalloproteinase-1 is a marker of diastolic dysfunction using tissue Doppler in patients with type 2 diabetes and hypertension. Eur J Clin Invest 35 (2005) 8-12
5. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases. Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113 (2006) 2089-2096
6. Zureik M., Beaudeux J.L., Courbon D., Benetos A., and Ducimetiere P. Serum tissue inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arterial stiffness. J Hypertens 23 (2005) 2263-2268
7. Lubos E., Schnabel R., Rupprecht H.J., et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 27 (2006) 150-156
8. Cavusoglu E., Ruwende C., Chopra V., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 151 (2006) 1101.e1-1101.e8
9. Tayebjee M.H., Lip G.Y., Tan K.T., et al. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96 (2005) 339-345
10. Tayebjee M.H., Karalis I., Nadar S.K., et al. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension. Am J Hypertens 18 (2005) 325-329
11. Feinbloom D., and Bauer K.A. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25 (2005) 2043-2053
12. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. An individual participant meta-analysis. JAMA 294 (2005) 1799-1809
13. Vlachopoulos C, Aznaouridis K, Dima I, et al., Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int J Cardiol; in press.
14. Vlachopoulos C., Dima I., Aznaouridis K., et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 112 (2005) 2193-2200
15. Johnson J.L., Baker A.H., Oka K., et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2. Involvement of macrophage migration and apoptosis. Circulation 113 (2006) 2435-2444
16. Cavallaro G., Cucina A., Randone B., et al. TIMP-2 modulates neointimal formation in experimental ePTFE arterial grafts. J Surg Res 137 (2007) 122-129
17. Baker A.H., Zaltsman A.B., George S.J., and Newby A.C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101 (1998) 1478-1487
18. Howard E.W., Bullen E.C., and Banda M.J. Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 266 (1991) 13070-13075
19. Pla-Rodriguez A., Bosch-Gil J.A., Rossello-Urgell J., et al. Metalloproteinase-2 and -9 in giant cell arteritis. Involvement in vascular remodeling. Circulation 112 (2005) 264-269
20. Strongin A.Y., Collier I., Bannikov B.L., Grant G.A., and Goldberg G.I. Mechanism of cell surface activation of 72kDa type IV collagenase. J Biol Chem 270 (1995) 5331-5338
21. Tronc F., Mallat Z., Lehoux S., et al. Role of matrix metalloproteinases in blood flow-induced arterial enlargement. Interaction with NO. Arterioscler Thromb Vasc Biol 20 (2000) e120-e126